Voyager Therapeutics (VYGR) Stock Price, News & Analysis

Company Overview

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Key Stats

• Today's Range: $5.62 to $5.85
• 50-Day Range: $5.27 to $8.07
• 52-Week Range: $5.19 to $11.72
• Volume: 267,367 shs
• Average Volume: 627,506 shs
• Market Capitalization: $313.01 million
• P/E Ratio: 8.07
• Dividend Yield: N/A
• Price Target: $17.00
• Consensus Rating: Buy

Voyager Therapeutics Stock Analysis - MarketRank™

Voyager Therapeutics scored higher than 92% of companies evaluated by MarketBeat, and ranked 78th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Voyager Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Voyager Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Voyager Therapeutics are expected to decrease in the coming year, from ($0.89) to ($1.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Voyager Therapeutics is 8.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.36.

Price to Earnings Ratio vs. Sector

The P/E ratio of Voyager Therapeutics is 8.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.05.

Price to Book Value per Share Ratio

Voyager Therapeutics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.69% of the outstanding shares of Voyager Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Voyager Therapeutics has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Voyager Therapeutics has recently increased by 4.92%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Voyager Therapeutics does not currently pay a dividend.

Dividend Growth

Voyager Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.97

Percentage of Shares Shorted

4.69% of the outstanding shares of Voyager Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Voyager Therapeutics has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Voyager Therapeutics has recently increased by 4.92%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.50

News Sentiment

Voyager Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Voyager Therapeutics this week, compared to 6 articles on an average week.

Search Interest

10 people have searched for VYGR on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.

MarketBeat Follows

Only 8 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Voyager Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,914.00 in company stock.

Percentage Held by Insiders

Only 4.53% of the stock of Voyager Therapeutics is held by insiders.

Percentage Held by Institutions

48.03% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VYGR Stock Analysis - Frequently Asked Questions

How have VYGR shares performed this year?

Voyager Therapeutics' stock was trading at $8.44 at the start of the year. Since then, VYGR stock has decreased by 32.1% and is now trading at $5.73.
View the best growth stocks for 2024 here.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.29. The company had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a trailing twelve-month return on equity of 8.33% and a net margin of 15.80%.

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' top institutional investors include Geode Capital Management LLC (1.98%), Erste Asset Management GmbH (1.94%), Great Point Partners LLC (1.76%) and State Street Corp (1.64%). Insiders that own company stock include Neurocrine Biosciences Inc, Rock Ventures Iii LP Third, Ecor1 Capital, Llc, Robert W Hesslein, Sandell Jacquelyn Fahey, Robin Swartz, Todd Alfred Carter, Glenn Pierce and Julie Burek.
View institutional ownership trends.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Voyager Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 12/23/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VYGR
• CUSIP: N/A
• CIK: 1640266
• Web: www.voyagertherapeutics.com
• Phone: (857) 259-5340
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $17.00
• High Stock Price Target: $30.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +196.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.71
• Trailing P/E Ratio: 8.08
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $132.33 million
• Net Margins: 15.80%
• Pretax Margin: 16.35%
• Return on Equity: 8.33%
• Return on Assets: 6.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.45
• Quick Ratio: 8.45

Sales & Book Value

• Annual Sales: $163.78 million
• Price / Sales: 1.91
• Cash Flow: $2.77 per share
• Price / Cash Flow: 2.07
• Book Value: $5.37 per share
• Price / Book: 1.07

Miscellaneous

• Outstanding Shares: 54,626,000
• Free Float: 52,151,000
• Market Cap: $313.55 million
• Optionable: Optionable
• Beta: 0.90